Brief: Lyra Therapeutics Presents Positive Data From Study Of LYR-210

Lyra Therapeutics

29/04/2022 14:43

April 29 (Reuters) - Lyra Therapeutics Inc  LYRA.O :
    * LYRA THERAPEUTICS PRESENTS POSITIVE DATA FROM LANTERN
PHASE 2
STUDY OF LYR-210 FOR TREATMENT OF CHRONIC RHINOSINUSITIS AT COSM
2022
    * LYRA THERAPEUTICS INC - LYR-210 ACHIEVED SIGNIFICANT
IMPROVEMENT
IN EACH CRS SYMPTOM SUBDOMAIN OF SNOT-22 COMPARED TO CONTROL
    * LYRA THERAPEUTICS INC - LYR-210 PROVIDED UP TO 24 WEEKS OF
CLINICALLY MEANINGFUL GLOBAL SYMPTOM IMPROVEMENT IN CRS PATIENTS
    * LYRA THERAPEUTICS INC - LYR-210 MAY IMPROVE MENTAL AND
PHYSICAL
HEALTH AND QUALITY OF LIFE OF CRS PATIENTS

Source text for Eikon:  ID:nPn6dhD3a 
Further company coverage:  LYRA.O 

 ((Reuters.Briefs@thomsonreuters.com;))